Back

Cholesterol-independent coronary disease progression revealed by electronegative LDL and HDL subfractions despite optimal guideline-directed lipid therapy

30 August 2026 (11:09 - 11:21)
Organised by: Logo
Congress Presentation Part of: Risk, reduction, and results: lipid cases in focus Lipids ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Yu-Hsiang Wang

Taichung Veterans General Hospital, Taichung (Taiwan)

4 More presentations in this session

Presentation thumbnail
Sitosterolemia as a phenocopy of homozygous familial hypercholesterolaemia: a diagnostic challenge
Doctor V. Silva (Sao Paulo, BR)
Slides Video
Presentation thumbnail
Severe left ventricular outflow tract obstruction due to supravalvular aortic stenosis associated with homozygous familial hypercholesterolaemia in a young patient
Ms M. Bruni Ratto De Lima (Sao Paulo, BR)
Slides Video
Presentation thumbnail
Therapeutic challenges using lomitapide in patients with homozygous familial hypercholesterolemia in middle-income countries: analysis of three real-world cases.
Mr D. Ceron Caicedo (Cali, CO)
Slides Video
Presentation thumbnail
Chylomicronemia associated with APOA5 variants: report of two unrelated cases in Colombia with refractory severe hypertriglyceridemia.
Slides Video

Access the full session

Session thumbnail
Risk, reduction, and results: lipid cases in focus
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 11:09 CET
You may be interested in
thumbnail
Congress Presentation
Impact of intensive low-density lipoprotein cholesterol lowering therapy on intermediate stenosis in non-culprit vessels of acute coronary syndrome
31 August 2025
thumbnail
Webinar
Biomarkers of clinical utility in cardiovascular disease
17 December 2024
thumbnail
Congress Presentation
Risk factors control, remnant cholesterol, recurrent events and risk in patients with coronary heart disease. Our experiences
4 April 2025
thumbnail
Congress Presentation
Extension of coronary artery disease and resistance to lipid-lowering treatment. Value of Lp(a)
23 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources